From January 1, 2023 to March 31, 2023, the company has repurchased 0 shares, representing 0% for ?0 million. With this, the company has completed the repurchase of 2,052,808 shares, representing 3.72% for ?135.01 million under the buyback announced on November 3, 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
84.3 EUR | +1.93% | +6.10% | +40.03% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+40.03% | 4.59B | |
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.